Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Experience in Spain with the first patients in home hemodialysis treated with low-flow dialysate monitors.
Slon Roblero MF, Bajo Rubio MA, González-Moya M, Calviño Varela J, Pérez Alba A, Villaro Gumpert J, Cigarrán S, Vidau P, García Marcos S, Abáigar Luquin P, Coll Piera E, Gascón Mariño A, Espigares MJ, Molina MD, Molina P. Slon Roblero MF, et al. Among authors: gonzalez moya m. Nefrologia (Engl Ed). 2021 Aug 12:S0211-6995(21)00144-2. doi: 10.1016/j.nefro.2021.07.001. Online ahead of print. Nefrologia (Engl Ed). 2021. PMID: 34393002 Free article. English, Spanish.
Impact of dialysis modality on morbimortality of kidney transplant recipients after allograft failure. Analysis in the presence of competing events.
Beltrán Catalán S, Sancho Calabuig A, Molina P, Vizcaíno Castillo B, Gavela Martínez E, Kanter Berga J, González Moya M, Pallardó Mateu LM; Grupo Levante de Diálisis Peritoneal. Beltrán Catalán S, et al. Nefrologia (Engl Ed). 2021 Mar-Apr;41(2):200-209. doi: 10.1016/j.nefro.2020.12.007. Epub 2021 Feb 13. Nefrologia (Engl Ed). 2021. PMID: 33593605 Free article. English, Spanish.
Impact of dialysis modality on morbimortality of kidney transplant recipients after allograft failure. Analysis in the presence of competing events.
Beltrán Catalán S, Sancho Calabuig A, Molina P, Vizcaíno Castillo B, Gavela Martínez E, Kanter Berga J, González Moya M, Pallardó Mateu LM; Grupo Levante de Diálisis Peritoneal. Beltrán Catalán S, et al. Nefrologia (Engl Ed). 2021 Mar-Apr;41(2):200-209. doi: 10.1016/j.nefroe.2020.12.005. Epub 2021 May 24. Nefrologia (Engl Ed). 2021. PMID: 36165381 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 34167773
Skin reactions with the use of icodextrin in peritoneal dialysis patients.
Vizcaino Castillo B, Beltrán Catalán S, Molina Vila P, Gonzalez Moya M, Noguera-Morel L, Pallardó Mateu LM. Vizcaino Castillo B, et al. Nefrologia (Engl Ed). 2019 Mar-Apr;39(2):211-213. doi: 10.1016/j.nefro.2018.07.002. Epub 2018 Sep 26. Nefrologia (Engl Ed). 2019. PMID: 30268413 Free article. English, Spanish. No abstract available.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer.
Rodríguez-Gonzalez A, Carmona-Bayonas A, Hernandez San Gil R, Cruz-Castellanos P, Antoñanzas-Basa M, Lorente-Estelles D, Corral MJ, González-Moya M, Castillo-Trujillo OA, Esteban E, Jiménez-Fonseca P, Calderon C. Rodríguez-Gonzalez A, et al. Among authors: gonzalez moya m. Clin Transl Oncol. 2023 Dec;25(12):3492-3500. doi: 10.1007/s12094-023-03214-5. Epub 2023 May 29. Clin Transl Oncol. 2023. PMID: 37247131
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
15 results